PKO Investment Management Joint-Stock’s Gilead Sciences GILD Stock Holding History

PKO Investment Management Joint-Stock’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.39M	Buy	58,500 +9,500	+19%	+$1.25M	0.54%	42
2026 Q1	$6.83M	Buy	49,000 +10,000	+26%	+$1.4M	0.57%	43
2025 Q4	$4.79M	Buy	39,000 +1,000	+3%	+$122K	0.38%	59
2025 Q3	$4.22M	Buy	38,000 +29,000	+322%	+$3.3M	0.36%	62
2025 Q2	$998K	Buy	9,000 +6,000	+200%	+$639K	0.11%	126
2025 Q1	$336K	Sell	3,000 -3,000	-50%	-$310K	0.04%	166
2024 Q4	$554K	Buy	6,000 +3,000	+100%	+$270K	0.07%	139
2024 Q3	$252K	Sell	3,000 -3,000	-50%	-$229K	0.03%	152
2024 Q2	$412K	Sell	6,000 -4,000	-40%	-$267K	0.05%	152
2024 Q1	$736K	Buy	10,000 +5,000	+100%	+$384K	0.09%	133
2023 Q4	$405K	Sell	5,000 -5,000	-50%	-$389K	0.05%	134
2023 Q3	$749K	Sell	10,000 -5,000	-33%	-$385K	0.1%	108
2023 Q2	$1.16M	Buy	15,000 +5,000	+50%	+$399K	0.14%	100
2023 Q1	$830K	Buy	10,000 +8,000	+400%	+$663K	0.11%	115
2022 Q4	$172K	Sell	2,000 -7,000	-78%	-$554K	0.03%	134
2022 Q3	$555K	Sell	9,000 -5,000	-36%	-$315K	0.09%	111
2022 Q2	$865K	Sell	14,000 -11,000	-44%	-$681K	0.12%	100
2022 Q1	$1.49M	Sell	25,000 -13,366	-35%	-$854K	0.18%	91
2021 Q4	$2.79M	Sell	38,366 -31,177	-45%	-$2.15M	0.31%	66
2021 Q3	$4.86M	Buy	69,543 +31,807	+84%	+$2.23M	0.58%	47
2021 Q2	$2.6M	Buy	37,736 +23,262	+161%	+$1.55M	0.33%	57
2021 Q1	$935K	Hold	14,474	–	–	0.15%	67
2020 Q4	$843K	Hold	14,474	–	–	0.14%	62
2020 Q3	$915K	Hold	14,474	–	–	0.18%	60
2020 Q2	$1.11M	Hold	14,474	–	–	0.25%	56
2020 Q1	$1.08M	Hold	14,474	–	–	0.37%	52
2019 Q4	$941K	Hold	14,474	–	–	0.23%	63
2019 Q3	$917K	Hold	14,474	–	–	0.23%	67
2019 Q2	$978K	Hold	14,474	–	–	0.25%	65
2019 Q1	$941K	Hold	14,474	–	–	0.25%	66
2018 Q4	$905K	Hold	14,474	–	–	0.26%	63
2018 Q3	$1.12M	Hold	14,474	–	–	0.22%	59
2018 Q2	$1.03M	Sell	14,474 -4,717	-25%	-$333K	0.21%	63
2018 Q1	$1.45M	Hold	19,191	–	–	0.32%	52
2017 Q4	$1.37M	Buy	19,191 +6,666	+53%	+$506K	0.34%	54
2017 Q3	$1.01M	Buy	12,525 +2,548	+26%	+$195K	0.27%	55
2017 Q2	$706K	Buy	9,977 +5,112	+105%	+$340K	0.24%	55
2017 Q1	$330K	Buy	4,865 +4,098	+534%	+$288K	0.15%	59
2016 Q4	$54.9K	Buy	+767	New	+$57K	0.04%	62

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

PKO Investment Management Joint-Stock's GILD Position: Q2 2026 in Review

PKO Investment Management Joint-Stock increased its Gilead Sciences (GILD) stake by 19% in Q2 2026, buying an estimated $1.25M and bringing the position to 58,500 shares worth $7.39M. The position accounts for 0.54% of the portfolio, ranked #42.

PKO Investment Management Joint-Stock first reported a position in GILD in Q4 2016 and has held it in 39 quarters since. 1,412 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

PKO Investment Management Joint-Stock held 58,500 shares of Gilead Sciences worth $7.39M as of Q2 2026.
PKO Investment Management Joint-Stock bought 9,500 Gilead Sciences shares in Q2 2026, an estimated $1.25M.
Gilead Sciences made up 0.54% of PKO Investment Management Joint-Stock's portfolio in Q2 2026, its #42 holding.
PKO Investment Management Joint-Stock first reported a position in Gilead Sciences in Q4 2016 and has held it in 39 quarters since.
1,412 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on PKO Investment Management Joint-Stock's 13F filing for Q2 2026, filed 20 Jul 2026.